HC Wainwright Weighs in on Cybin’s Q2 Earnings (NYSE:CYBN)

Cybin Inc. (NYSE:CYBN) – Investment analysts at HC Wainwright lowered their Q2 2026 earnings estimates for shares of Cybin in a research report issued on Monday, August 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.74) for the quarter, down from their previous estimate of ($0.56). The consensus estimate for Cybin’s current full-year earnings is ($4.76) per share. HC Wainwright also issued estimates for Cybin’s Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($1.57) EPS, FY2029 earnings at $5.17 EPS and FY2030 earnings at $7.47 EPS.

Several other equities research analysts also recently issued reports on the stock. Canaccord Genuity Group cut their target price on shares of Cybin from $73.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, July 8th. Cantor Fitzgerald upgraded shares of Cybin to a “strong-buy” rating in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $85.00.

Cybin Stock Performance

Shares of NYSE:CYBN opened at $6.60 on Wednesday. Cybin has a 52-week low of $4.81 and a 52-week high of $13.88. The company has a market capitalization of $155.69 million, a P/E ratio of -1.51 and a beta of 0.68. The company has a 50-day simple moving average of $7.74 and a 200 day simple moving average of $7.60.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. National Bank of Canada FI increased its holdings in shares of Cybin by 3,546.5% during the first quarter. National Bank of Canada FI now owns 5,251 shares of the company’s stock worth $33,000 after purchasing an additional 5,107 shares during the period. Marshall Wace LLP bought a new position in shares of Cybin during the fourth quarter worth approximately $94,000. Cowa LLC increased its holdings in shares of Cybin by 12.8% during the second quarter. Cowa LLC now owns 13,200 shares of the company’s stock worth $111,000 after purchasing an additional 1,500 shares during the period. PEAK6 LLC bought a new position in shares of Cybin during the first quarter worth approximately $167,000. Finally, Bank of America Corp DE increased its holdings in shares of Cybin by 66.8% during the second quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after purchasing an additional 11,790 shares during the period. 17.94% of the stock is owned by institutional investors.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.